// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer.

Sebastien J. Hotte - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Shaan Dudani - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

Effects of a 6-month moderate-intensity exercise program on metabolic parameters and bone mineral density in men on androgen deprivation therapy for prostate cancer.

Shabbir M.H. Alibhai - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Influence of aggressive-variant prostate cancer (AVPC) features on outcome of metastatic hormone-sensitive prostate cancer (mHSPC) treated by chemohormonal therapy (CHT).

Kim Koczka - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

Loss of RSPO3 as a potential mechanism of greater invasiveness in prostate cancer.

Aruz Mesci - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.

Marie-France Savard - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Sunitinib

Aspartyl (Asparaginyl) ß hydroxylase (AABH) as a serum bio-marker for prostate cancer to identify prostate cancer, regardless of PSA level.

Mahmood Moshiri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Outcomes in patients (Pts) with advanced prostate cancer and inactivating germline mutations in BRCA2 or ATM.

Steven Yip - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Perspectives of prostate cancer patients about active surveillance.

Fred Saad - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).

Ziad Bakouny - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear cell renal carcinoma

N/A

World maternal mental health day

A.Bowen - European Congress of Psychiatry (EPA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Evaluating the impact of survivorship models on health system resources and costs.

Nicole Mittmann - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Educating primary care providers about cancer survivorship.

Genevieve Chaput - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Patterns and predictors of attendance at a comprehensive, multi-disciplinary supportive care program for men with prostate cancer and their partners.

Lindsay Hedden - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Barriers of EQ5D-5L implementation into routine clinical practice: A multisite evaluation.

Justine Baek - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Breast cancer survivors' self-reported outcomes following an end of treatment group intervention.

Genevieve Chaput - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Engaging breast cancer survivors in their survivorship care.

Genevieve Chaput - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Nutrition services for men with prostate cancer: A health professional survey.

Kaity McLaughlin - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Impact of immigration status on health behaviors and perceptions in cancer survivors.

Sophia Yijia Liu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Ascertaining cancer survivors in Ontario using the Ontario Cancer Registry and administrative data.

Munaza Chaudhry - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved